Overview of Laktomag B6

Property	Description
Active Ingredients	Magnesium Aspartate, Pyridoxine Hydrochloride (Vitamin B6)
Form	Oral Tablet, Oral Solution
Pharmacological Class	Macro- and Microelement Supplement, Vitamin-Mineral Complex
Common Purpose	Deficiency Correction (Magnesium and Vitamin B6)
Origin	Derived (salts and synthetic compounds)

Laktomag B6: A Vitamin-Mineral Combination

Laktomag B6 is defined as a pharmaceutical preparation and a fixed-dose combination product belonging to the pharmacological class of macro- and microelement supplements and vitamin-mineral complexes. This classification indicates its primary role is to furnish the body with two essential nutrients simultaneously, distinguishing it from single-ingredient supplements. The preparation is made available in both oral tablet and a rapidly absorbable solution for oral use forms, both administered via the oral route (per os). Magnesium supplementation is recognized for its fundamental importance in regulating muscle relaxation and neuromuscular excitability. This characteristic supports the medicine's role in helping to maintain proper nerve and muscle function.

Composition and Origin: Magnesium Aspartate and Pyridoxine

The active ingredients in Laktomag B6 are Magnesium Aspartate and Pyridoxine Hydrochloride (Vitamin B6). The product is a derived combination of synthesized salts and compounds, not a natural extract. The selection of the Magnesium Aspartate salt is deliberate, as it is chosen for its characteristic high bioavailability compared to inorganic forms like magnesium oxide. Given the common co-occurrence of magnesium deficiency with vitamin B6 deficits, combining Magnesium with Vitamin B6 is a logical strategy to address linked nutritional deficits. Furthermore, the co-administered Pyridoxine actively assists in the cellular uptake and retention of the Magnesium, optimizing the mineral's functional availability throughout the body.

Primary Purpose: Addressing Essential Nutrient Deficiency

The general therapeutic purpose of this preparation is the correction of documented states of Magnesium deficiency and concurrent Vitamin B6 deficiency. The preparation works to restore systemic balance, primarily by reducing the neuromuscular excitability that is a symptom of low magnesium levels. By ensuring adequate supplies of these essential nutrients, the product helps relieve non-specific symptoms such as involuntary muscle cramps or spasms, and generalized fatigue or irritability linked to these specific nutrient depletions.

Regulatory References

NIH Office of Dietary Supplements Fact Sheet

What side effects are possible with Laktomag B6?

Possible side effects and safety information

The safety profile of Laktomag B6, a combination of Magnesium Aspartate and Pyridoxine Hydrochloride (Vitamin B6), is structured by government regulatory documents based on the potential effects of its two active components.

Adverse Reaction Scope

The most commonly documented adverse reactions are associated with the Gastrointestinal disorders system, often including diarrhea, nausea, or abdominal discomfort due to the presence of magnesium salts. Less frequently, reactions involving the Immune System and Skin and subcutaneous tissue disorders, such as hypersensitivity or allergic skin reactions (e.g., pruritus, urticaria), have been reported, though their frequency is typically classified as Not known based on available data.

Serious Safety Considerations

Two serious conditions are documented in regulatory information relating to its components:

Hypermagnesemia: A serious elevation of magnesium levels, presenting the highest risk in individuals with compromised renal function.
Severe Peripheral Neuropathy: Neurological damage associated with long-term exposure to high doses of the Pyridoxine (Vitamin B6) component.

Population-Specific Restrictions

Official prescribing information defines specific safety limitations. The preparation is contraindicated in patients presenting with Severe Renal Failure (e.g., Creatinine Clearance less than 30 ml/min) due to the substantial risk of accumulating magnesium, leading to hypermagnesemia. Use is also restricted in cases of known hypersensitivity to the active substances or pre-existing Hypermagnesemia. These official classifications define the strict boundaries for the medicine’s use.

Overdose and Emergency Response

Overdose on Laktomag B6 primarily involves hypermagnesemia, the systemic excess of the magnesium component. Initial documented signs of intoxication include flushing, sweating, nausea, vomiting, and somnolence (drowsiness). As serum concentrations rise, the overdose causes muscle weakness and the depression or loss of deep tendon reflexes (DTRs).

Immediate medical attention or contact with emergency services is required upon recognizing signs of suspected overdose. The product must be discontinued immediately. Severe, life-threatening outcomes officially documented include severe hypotension, respiratory paralysis, and severe cardiac conduction abnormalities that can lead to cardiac arrest and coma.

In these severe cases, an injectable calcium salt must be made immediately available for administration as the specific antidote for magnesium toxicity. Supportive care, including potential hemodialysis for severe cases, is officially described. Regulatory documents note that patients with renal impairment are at a greater risk for developing severe magnesium intoxication due to impaired clearance. Chronic, excessive intake of the vitamin component ( Pyridoxine) is associated with sensory neuropathy.

Therapeutic Uses of Laktomag B6

The preparation Laktomag B6 is applied in clinical contexts where Magnesium deficiency and often co-occurring Vitamin B6 deficiency are established or suspected to be contributing to symptomatic discomfort. It is used in situations involving symptomatic support across key domains of the nervous and muscular systems. Within this therapeutic area, magnesium deficiency is associated with symptoms such as muscle cramps and personality changes.

The preparation is commonly used to help with symptom clusters that may appear suddenly or intensify over time, including involuntary muscle symptoms (cramps, spasms), neuro-psychological manifestations like elevated irritability and nervousness, and persistent, generalized fatigue and tiredness. The relief provided by addressing these linked nutrient deficits is intended to help with symptom fluctuations during periods of heightened discomfort.

The supportive relief may help with managing distressing manifestations like nocturnal calf cramps and minor sleep disturbances caused by restlessness, ultimately contributing to easing the overall symptom load and assisting with the maintenance of functional stability.

Quick Support for Musculoskeletal Symptoms

Laktomag B6 is relevant in clinical settings where symptoms of increased neurological or muscular activity lead to temporary functional strain, such as involuntary muscle spasms or twitching, and is applied when short-term symptomatic assistance is needed for managing discomfort.

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Information

Laktomag B6 (Magnesium Aspartate and Pyridoxine Hydrochloride) is formally classified for use based on specific patient populations and existing health conditions, as defined in regulatory documentation.

Contraindicated Populations

Use is absolutely contraindicated in patients with severe renal impairment (glomerular filtration rate less than 30 ml/min) and those with established disorders of cardiac conduction (including bradycardia). Individuals with known hypersensitivity to the active substances or any excipients must not use the medicine. The oral solution form is also contraindicated for patients with certain hereditary metabolic disorders, such as fructose intolerance.

Restricted and Conditional Use

Use requires caution in patients with non-severe renal impairment, existing heart disease, or specific neuromuscular diseases like myasthenia gravis. The oral solution requires consideration for patients with diabetes mellitus due to its excipient content.

Age and Physiological Status

Use is generally permitted for adults. While certain dosage strengths are not recommended for children, the medicine is officially permitted for use during pregnancy when clinically necessary and is also permitted while breastfeeding, as no adverse effects on the infant are anticipated at therapeutic doses.

What should I know about interactions with other medicines?

The official regulatory profile for Laktomag B6, a combination of Magnesium Aspartate and Pyridoxine Hydrochloride, details specific pharmacokinetic and pharmacodynamic interactions.

Interaction-Related Restrictions

Classification	Constraint
Contraindicated	The Pyridoxine component is officially restricted for co-administration with Levodopa when the latter is used without a peripheral dopa decarboxylase inhibitor, as it may reduce the therapeutic effect of Levodopa.
Population-Specific	The risk of accumulated magnesium and its associated effects, such as hypermagnesemia, is heightened and monitored more closely in patients with renal impairment (kidney insufficiency).

Exposure-Modifying Substances

Magnesium, a divalent cation, is documented to reduce the oral absorption of several co-administered medicines through chelation, resulting in decreased systemic exposure and lower efficacy of the interacting drug. These include:

Oral Tetracycline-class Antibiotics and Quinolone-class Antibiotics
Oral Bisphosphonates (e.g., Alendronate) and Digoxin
Certain Integrase Strand Transfer Inhibitors

Administration Timing Rules

To mitigate the chelation-based pharmacokinetic interaction, official regulatory labeling mandates specific timing separation. Laktomag B6 must be administered at least two hours before or four to six hours after certain antibiotics, and generally separated by at least two hours from bisphosphonates.

Pharmacodynamic Effects

Co-administration with other agents may lead to additive effects. The Magnesium component may enhance the hypotensive effect of Calcium Channel Blockers or potentiate the effects of Muscle Relaxants. Co-administration with other Magnesium-containing products increases the risk of magnesium accumulation.

Mechanism of Action

How Laktomag B6 Works

The mechanism of Laktomag B6 involves the coordinated action of its two components across key biological systems, primarily focusing on cellular regulation and neuromuscular function.

Modulating Nerve and Muscle Excitability

This domain covers the mineral component's role in regulating ion flow across cell membranes. By modulating channels for ions like calcium, the mechanism supports the stabilization of the electrical potential of excitable cells, which helps reduce inappropriate or excessive firing of motor nerves and supports the regulated maintenance of muscle function.

Supporting Metabolic Function and Energy Transfer

The mineral is an essential cofactor for hundreds of enzymatic processes, most crucially those governing ATP synthesis and transfer. This action helps maintain the vital, high-energy molecule ATP, which is required for sustained enzymatic and transport processes throughout the body, supporting the fundamental metabolic processes necessary for cellular activity.

Enhancing Cellular Bioavailability

The vitamin B6 component acts synergistically to increase the cellular uptake and retention of the mineral. By facilitating transport and reducing the mineral's loss through the kidneys, this mechanism ensures sustained availability at the intracellular sites where the enzyme cofactor and membrane stabilizing actions occur, thereby supporting the duration and magnitude of the primary mechanistic consequences.

Dosage and Administration Information

How to Use Laktomag B6

This section outlines the instructions for the administration of Laktomag B6, focusing on dosage, frequency, and preparation requirements.

Administration Route and Dosing

The route for this preparation is oral use. The product is available as an oral tablet and an oral solution or powder. The standard adult daily dose for correcting nutrient deficiency typically ranges from 243 mg to 486 mg of elemental magnesium. Dosing for children is typically determined by the child’s age or weight group, rather than a standard adult measure.

Frequency and Preparation

The total daily dose is generally administered in divided doses throughout the day (e.g., two to three times daily) to optimize absorption. If using the powder or solution form, dilution is required prior to intake. The preparation must be dissolved in a specified volume of liquid, such as 50 mL to 200 mL of water or juice, before consumption. Tablets are typically administered with meals along with sufficient fluid.

Procedural Constraints and Duration

To prevent the impaired absorption of the active ingredients, a time interval of 2 to 4 hours must be maintained between taking Laktomag B6 and certain other oral medicines, such as iron salts or bisphosphonates. No dose adjustment is generally specified for older adults. The duration of treatment is not fixed but continues until the underlying nutrient deficiency has been corrected.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Laktomag B6

Evidence for Symptoms Related to Low Magnesium and Stress

This section will summarize the structure of Randomized Controlled Trials (RCTs) that have examined the Magnesium and Vitamin B6 combination's association with measured changes in stress, anxiety, and general discomfort in adult populations.

Research has explored the use of the Magnesium and Pyridoxine (Vitamin B6) combination in studies conducted during periods of increased symptom activity related to systemic or functional imbalance. The research examined outcomes monitoring physiological strain or stress, using validated psychological scales to measure changes in stress, anxiety, and depressive symptoms over the study intervals. Findings describe patterns observed in the studies, where studies reported changes in measurements on the stress and anxiety scales over the 4- to 8-week study period. Some trials described that the combination was associated with differing patterns of change compared to magnesium alone. However, long-term effects are not fully established regarding symptomatic patterns or maintenance of magnesium status.

Research Structure for Skeletal Muscle Cramps

This part will focus on the Systematic Reviews and Meta-analyses conducted on magnesium monotherapy concerning its effect on cramp frequency and intensity, outlining the study designs and outcomes evaluated for this neuromuscular symptom.

The evidence base for the use of this preparation for involuntary muscle cramps largely comes from Systematic Reviews and Meta-analyses of older, often short-term, studies of magnesium monotherapy (magnesium used alone). Research describes that when magnesium monotherapy was studied for idiopathic cramps in older adults, the evidence suggests that measured changes in cramp frequency were often not discernible in the study populations. The evidence is limited because this research mostly explores magnesium alone, and comparative evidence examining the Magnesium and Vitamin B6 combination specifically for muscle cramps is lacking.

Long-Term Studies and Durability of Response

Studies observing responses over defined time intervals have primarily focused on short-term symptom changes, typically assessing outcomes for only 4 to 8 weeks. These follow-up durations were limited, meaning the studies provide insight into short-term changes but not the durability of these patterns over many months or years. Long-term data points for these changes are not characterized by the short-term trials available.

Evidence in Special Populations and Subgroups

The combination was studied for stress-related outcomes specifically in adults with low magnesium levels. The magnesium monotherapy research applied in studies examining patient-reported experiences related to skeletal muscle cramps includes data for both pregnant women and older adults. However, subgroup findings are uncertain, particularly regarding the use of the fixed-dose combination in older adults, children, or individuals with other underlying health conditions.

Limitations and Research Gaps

One key gap is that the sample sizes were modest in some specific trials, restricting the broad applicability of the findings. The evidence quality varies across studies, particularly when comparing modern RCTs with older monotherapy data. A significant area of uncertainty is the specific role of Vitamin B6 (Pyridoxine) in influencing symptomatic changes remains an area of uncertainty. Research has reported mixed and inconsistent findings, and comparative evidence is lacking to definitively clarify its role in outcomes related to stress or muscle discomfort.

Frequently Asked Questions (FAQ)

Common questions about Laktomag B6 (FAQ)

Q: What is the difference between Laktomag B6 and a standard magnesium supplement?

Laktomag B6 is defined in official regulatory documents as a fixed-dose combination product and a vitamin-mineral complex. The preparation contains two active substances: Magnesium Aspartate and Pyridoxine Hydrochloride (Vitamin B6). This combination product is distinct from a standard supplement that contains only a single magnesium ingredient.

Q: Is Laktomag B6 intended for long-term or short-term use?

Official product information states that treatment duration continues until the underlying nutrient deficiency has been corrected. Long-term use of high doses of the Vitamin B6 component has been associated with a risk of a condition called Severe Peripheral Neuropathy (nerve damage). For this reason, continuous use is typically monitored due to this risk.

Q: Are there different safety considerations or side effects of Laktomag B6 in children compared to adults?

Official regulatory documents state that dosing for children is determined based on their age or weight group, rather than a standard adult dose. Furthermore, the use of certain dosage strengths of the medicine is not recommended for the pediatric population. This highlights that there are different safety and usage considerations compared to adults.

Q: What are the general signs that someone may be taking more Laktomag B6 than is appropriate?

A serious complication of taking too much magnesium is called hypermagnesemia, or excessive magnesium in the blood. Signs of this condition can include weakness, confusion, decreased breathing rate, and low blood pressure. In the most serious cases, regulatory documents warn that cardiac complications may occur.

Q: Does Laktomag B6 contain any ingredients that are considered common food allergens?

Official documents require the presence of substances like lactose, wheat starch, or other materials to be noted along with a warning for patients with known hypersensitivity. This information is found in the excipients list of the product's official regulatory documentation.

Q: Is Laktomag B6 specifically indicated as suitable for older adults (seniors)?

Official guidance generally states that no dose adjustment is specified for older adults. However, research summaries suggest that specific findings regarding the efficacy and suitability of the fixed-dose combination in this patient subgroup may sometimes be uncertain. Official guidance notes that caution is often indicated for older adults with pre-existing conditions.

Q: Are there official documents discussing Laktomag B6 use in infants or toddlers?

Official product labeling provides specific dosing information based on the child’s age or weight group for when the medicine is permitted for pediatric use. However, regulatory documents may state that certain dosage strengths are not recommended for young children due to the concentration of active ingredients.

Q: What type of research evidence is available concerning Laktomag B6's use in relation to fatigue?

Regulatory summaries indicate the preparation is used to relieve common non-specific symptoms like generalized fatigue or irritability when these are linked to nutrient depletion. The official research that exists primarily covers studies examining outcomes related to physiological strain or stress.

Q: What is the recommended action if a dose of Laktomag B6 is occasionally missed?

Patient information typically advises against taking a double dose to try and make up for one that was forgotten. Patient information describes the common approach, which is to either take the dose as soon as it is remembered or to skip it entirely if the next dose is already due soon.

Q: Is headache a commonly reported adverse event associated with Laktomag B6?

Headache is not universally classified as a common adverse event of this product in regulatory documents. However, official information does mention that both deficient and excessively high magnesium levels in the body can potentially be associated with headache or migraine symptoms.

Q: Does official information address Laktomag B6 affecting one's ability to drive or operate machinery?

Regulatory documents include a specific section addressing the influence of the medicine on the ability to drive and use machines. This information typically states that the product has no or negligible influence, unless side effects like dizziness or drowsiness are listed, which would require a specific warning.

Q: Is it suggested to separate the timing of Laktomag B6 from calcium supplements?

Official regulatory guidance often documents a time interval of 2 to 4 hours between the intake of Laktomag B6 and other mineral supplements, such as calcium. This separation is documented to address the potential for impaired absorption of the active ingredients due to competitive mineral interaction.

Q: Does official guidance mention the effect of alcohol consumption on Laktomag B6?

While specific warnings may vary, some regulatory information advises that regular alcohol consumption can potentially decrease the absorption and reduce the overall bioavailability of B-vitamins. This effect relates specifically to the Pyridoxine component of this medicine.

Q: Is Laktomag B6 generally suitable for people with celiac disease or gluten sensitivity?

Regulatory documents specify if the product contains excipients like wheat starch or gluten-containing derivatives. If these are present, a warning restricting use for celiac patients is typically included in the patient information leaflet.

Q: Why do some online users report feeling drowsy after taking Laktomag B6?

Drowsiness, or somnolence, is sometimes classified in regulatory documents as an uncommon or rare adverse event. When such effects are noted, even if rare, the official documentation requires a warning regarding performing tasks that demand alertness, such as driving or operating machinery.

Q: How is the effectiveness of Laktomag B6 typically monitored or assessed in clinical and research settings?

Effectiveness in deficiency correction is typically monitored by measuring serum or blood magnesium levels through laboratory tests. It is also assessed by observing the clinical resolution of neuromuscular excitability symptoms associated with the nutrient deficiency.

How should Laktomag B6 be stored and disposed of?

How to Store and Dispose of Laktomag B6

Storage of Laktomag B6 (Magnesium Aspartate and Pyridoxine Hydrochloride) must align with official regulatory requirements to maintain product stability and integrity.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store below 25 C
Protection	Must be protected from light, moisture, and frost
Packaging	Keep in the original packaging
Shelf Life	Do not use after the labeled expiry date (shelf life is two years)

The medicine must also be kept out of the reach and sight of children. This mandatory safety instruction prevents accidental access.

Official regulatory documents reviewed do not contain specific, product-labeled instructions for the disposal of unused or expired Laktomag B6. Disposal should follow general local regulations for pharmaceutical waste.

Laktomag B6